Friday, 9th February 30th Lorne Cancer Conference 2018

• Role of the microenvironment in cancer invasion and therapy response - Erik Sahai
• Emerging role of liquid biopsy in colorectal cancer: detecting minimal residual disease and assessing treatment response - Jeanne Tie
• Re-educating The Tumour Microenvironment to Overcome Resistance - Ruth Ganss
• DCLK1 is a novel driver of gastric tumourigenesis - Michael Buchert
• Seeing is believing: Mapping the dynamic extracellular matrix in cancer. - Thomas Cox

• Harnessing kinase dependent and independent functions of RAF kinases to treat RAS mutant tumors - Shiva Malek
• In vivo models of acquired resistance reveal complex mechanisms behind treatment failure in pancreatic cancer and provide means for effective targeting - Marina Pajic
• The Emerging Role for BCL2 Inhibtion in Haematological Malignancy - Mary Ann Anderson
• CESTEM-1 clinical trials using dynamin inhibitors to reverse resistance to monoclonal antibody therapy - Shannon R Joseph
• Molecular targeted therapy for childhood cancer - Michelle Haber

• The regulation of p53 in human cancer - David Lane
• Caspase-2 as a suppressor of aneuploidy - Sharad Kumar
• Restoration of TET function as a therapeutic strategy in leukemia - Luisa Cimmino
• AR chromatin binding events get reprogrammed in the absence of FOXA1 in ER negative breast cancers - Iza Denis
• Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small cell lung cancer with an altered metabolism - Sarah A Best
• Unravelling the role of cell plasticity in BrCa development and metastasis - Beatriz Perez San Juan
• A novel familial AML syndrome with a distinctive mutational signature and common driver mutations due to germline MBD4 loss - Edward Chew
• Over-expression of MYC drives aggressive Small Cell Lung Cancer in vivo - Jasmine Chen
• RIG-Ing lung cancer to death - Karishma Sachaphibulkij

Flash Talk Posters #201-#206

• Personalising lung radiotherapy: using functional lung imaging and translational radiobiology to drive a comprehensive risk adapted treatment strategy - Nicholas Bucknell
• Using functional and genomic assays of radiosensitivity to investigate radiation-induced second cancer - Mohammed Habash
• Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signalling - Hongbin Liu
• A translational study in non-small cell lung cancer radiotherapy patients – a search for novel biomarkers of normal tissue toxicity - Diane Russo
• Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer - Morghan C Lucas
• Exosomes derived from Glioma Stem Cells (GSCs) promote cell progression and radiation resistance in brain cancer. - Chenkai Ma
• The role of ZYG11 family members in development and disease - Charlene Magtoto
• Using cucurbiturils to deliver chemotherapeutics to metastases via the EPR effect - Ruqaya Maliki
• A Knock-In model for JAK3^A572V activating mutation reveals its intimate link to T cell hematopoietic disorders in vivo - Sebastien Malinge
• A role for NK cells in melanoma response to targeted therapies - Claire Martin
• Organoid model of transgenic fallopian tube secretory epithelial cells – A tool for the study of high grade serous ovarian cancer  - Ellen Mathieson
• The nonsense mutant of the Hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways - Isao Matsuura
• Adoptive transfer of genetically engineered monocytes for the tumour targeted delivery of IFN-alpha in breast cancer - Roberta Mazzieri
• Investigation of prodrug combinations that facilitate doxorubicin-DNA adducts and elucidation of transcriptomic responses - Sean McGrath
• Effects of doxorubicin and ABT-737 on breast cancer: A real-time perspective - Terri Meehan-Andrews
• Obesity related factors in relation to epithelial ovarian cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC) study - Melissa A Merritt
• The epigenetic landscape of paediatric acute myeloid leukaemia   - Braydon Meyer
• Mammary stem cell hierarchy maintenance by GPSM2 and asymmetric cell division - Michal Milgrom Hoffman
• UNRAVELLING THE COMPLEXITY OF ANDROGEN RECEPTOR SIGNALLING IN ER+/AR+ ENDOCRINE-RESISTANT BREAST CANCER - Heloisa Helena Milioli
• Identifying Smac-mimetic combination therapies for the treatment of resistant acute myeloid leukaemia - Emma Morrish
• Manipulating c-MYC expression as a therapeutic strategy for gastric cancer - Riley J Morrow
• Transient tissue ‘priming’ via FAK inhibition to impair pancreatic ductal adenocarcinoma (PDAC) progression and improve sensitivity to gemcitabine/Abraxane - Kendelle J Murphy
• Organoid models to investigate the role of immunotherapy in colorectal peritoneal metastases - Vignesh Narasimhan
• Understanding mechanisms of PARP inhibitor sensitivity and resistance in high-grade serous ovarian carcinoma - Ksenija Nesic
• Integrative network modelling predicts and rationalizes drug combinations - Lan K. Nguyen
• Intravital window imaging of RhoA-, Rac1- and Akt-FRET biosensor mice in normal tissue homeostasis, disease contexts and treatment. - Max Nobis
• A mutation in the viral sensor 2’-5’-oligoadenylate synthetase 2 causes failure of lactation - Samantha R Oakes
• MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. - Samantha R Oakes
• Ropporin-1 is a highly immunogenic and widely expressed antigen that induces specific antibody and T cell responses in melanoma patients - Simone Ostrouska
• Novel Tri(carbazole)benzene as G-quadruplex Stabilizing Ligands - Arnold Ou
• LOSS OF TUMOUR-INTRINSIC INTERFERON SIGNALLING DRIVES BONE-METASTATIC OUTGROWTH IN PROSTATE CANCER - Katie Owen
• Bacopaside II reduces endothelial cell migration and angiogenesis in vitro - Helen M Palethorpe
•   Inhibition of MYCN transcription by M606, a novel small molecule inhibitor identified through chemical library screening - Ruby Pandher
• Dual inhibition of JAK and Src: A novel and promising therapeutic combination for pancreatic cancer - Ashleigh L Parkin
• Bioengineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating CAF-induced malignancy in vitro - Brooke A Pereira
• DEAD-box RNA helicase DDX20 in redox-dependent regulation of Wnt/β-catenin signalling in triple-negative breast cancer - Sebastian Pohl
• Using structural information to guide the use of genomic sequencing in clinical oncology to improve patient outcomes. - Stephanie Portelli
• Inhibition of MDM2 synergises with endocrine and CDK targeted therapies - Neil Portman
• Investigating immune subsets in tumours in situ with multiplex immunohistochemistry - Marne Prinsloo
• Targeting MDM4- mutant p53 axis in treatment resistant advanced prostate cancer - Dinesh Raghu
• Pharmacological intervention in the eicosanoid pathway at phospholipase A2 in hepatocellular carcinoma cell lines - Anshuli Razdan
• Investigating the in vivo role of the Ehf transcription factor in intestinal epithelial differentiation and tumorigenesis - Camilla Reehorst
• Maskless quantitative multi-protein photopatterning by PRIMO to orchestrate cellular microenvironment  - Nandor Roczo
• Kinact: a web server for predicting activating mutations in protein kinases - Carlos H.M. Rodrigues
• Triterpenoid micellar nanoparticles for the treatment of glioblastoma: potential inhibition of the PI3K/Akt signalling - Rebecca H Roubin
• Design and development of a new oncology unit of study in the new integrated Master of Pharmacy curriculum - Rebecca H Roubin
• Novel G protein-coupled receptor regulating self-renewal in leukemia stem cells - a potential therapeutic target - Basit Salik
• c-Myc and Metabolic Reprogramming in Liver Cancer - Talhah Salmi
• Targeting nucleolar DNA damage response as a novel therapeutic strategy for high-grade serous ovarian cancer - Elaine Sanij
• The expression of miR-143, miR-214 and miR-223 in malignant pleural mesothelioma xenograft tumours is primarily from stromal cells. - Kadir H Sarun
• Fibroblast Growth Factor signals stimulate cell growth, EMT and malignant behaviour in malignant pleural mesothelioma - Karin Schelch
• Is there a role for DNA methylation in malignant transformation of paediatric brain tumours? - Alexandra Sexton-Oates
• Cell cycle checkpoint inhibition enhances conventional glioblastoma treatments - Tracy Seymour
• RGB marking to characterise treatment-resistant subpopulations in colorectal cancer - Carolyn Shembrey
• Tracking cell division and viability during in vitro drug treatment using fluorescent time-lapse imaging. - Kristy L Shield-Artin
• A double targeted strategy for effective drug delivery to brain metastases - Sarah Shigdar
• Development of a 6-Plex digital immunoassay for detection of immuno-oncology markers - Brenton Short
• An Integrated Pipeline to analyse the structural and molecular effects of mutations in cancer - Vasishth Sidarala
• Functional genomic screens for modifiers of trastuzumab emtansine sensitivity - Kyla N Siemens
• Predicting the consequences of missense variants using a measure of genic intolerance - Michael Silk
• Anti-tumour effects of Bacopaside II on colorectal cancer cells in vitro - Eric Smith
• RNA binding kinase UHMK1 facilitates therapy induced metabolic adaptation in BRAF^V600 melanoma - Lorey Smith
• Scribble on the edge: localisation of a tumour suppressor - Rebecca Stephens
• Manipulating cell cycle checkpoints to boost radiation effectiveness for paediatric medulloblastoma - Brooke S Strowger
• Invasive lobular breast cancer: Using tumour genome-wide DNA methylation to further subtype and aid in the identification of susceptibility genes. - Medha Suman
• Discovery of new therapy targets in HER2-enhanced breast cancer (HEBC) using transposon mutagenesis screen - Bill Tang
• Investigating the origin of aggressive subtypes of castration-resistant prostate cancer - Roxanne Toivanen
• In the absence of apoptosis myeloid cells arrest when deprived of growth factor but remain viable without atg5-dependent autophagy or uptake of glucose or glutamine - Hoanh Tran
• PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation - Candani Tutuka
• Regulators of genetic risk of the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma identified by transcriptional network reconstruction approach - Dora Lucia Vallejo Ardila
• Exploration of novel regulators of mutant p53 in cancer cells - Reshma Vijayakumaran
• Targeting copper in Neuroblastoma with a natural derived compound. - Orazio Vittorio
• Investigating cellular responses in blood cancers when targeting the thioredoxin system with a gold compound - Sicong Wang
• Modelling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids - James R Whittle
• PTPN2-deficiency enhances T cell mediated anti-tumour immunity - Florian Wiede
• Inhibition of HER2 positive breast cancer using antiandrogen therapies - James Williams
• Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans. - Jean M Winter
• Single-cell RNA sequencing reveals the heterogeneity of cancer-associated stromal cells in triple negative breast cancer - Sunny Z Wu
• Combined inhibition of HDACs and histone chaperone FACT leads to complete neuroblastoma regression in Th-MYCN transgenic mice - Lin Xiao
• Activation of nucleolar DNA damage response as a therapeutic strategy for ovarian cancer - Jiachen Xuan
• Autophagy inhibition sensitizes liver cancer stem cells to the treatment of doxorubicin - Wang Yin
• Overcoming therapeutic resistance to PI3K inhibition in breast cancer - Kelvin Yip
• Investigating thioredoxin dimer formation as a regulatory mechanism for its reductase activity - Yali Zhang
• Analysis of anticancer activity of Kakadu plum extracts against Multiple Myeloma cells - Yuan Zhang
• Harnessing senescence to control oncogene-driven cancer through metabolic intervention - Haoran Zhu